Otorhinolaryngology Department, Faculty of Medicine, Canakkale Onsekiz Mart University, Turkey.
Faculty of Science and Literature, Department of Molecular Biology and Genetics, Çanakkale Onsekiz Mart University, Turkey.
Arch Med Res. 2022 Nov;53(7):711-717. doi: 10.1016/j.arcmed.2022.10.003. Epub 2022 Oct 26.
The purpose of this study was to determine whether the mitochondrial DNA (mitDNA) copy number in blood samples of patients with thyroiditis, benign nodules or malignant nodules is different from that in healthy individuals, and to examine whether mtDNAcn has the ability to distinguish between different thyroid diseases.
This study consists of principal groups as thyroid patients and control group. The thyroid patient group comprised 30 patients with malignant nodules, 33 with benign nodules and 31 with thyroiditis, whereas the control group was composed of 21 healthy individuals. Blood samples were collected from the patients before treatment. Results were evaluated between groups.
We could not find an adequate number of participants for inclusion to match the groups. Similarly, since there is a gender difference in terms of disease prevalence, it was not possible to pair the populations in terms of gender. Instead, the results were analyzed with an adjusted model, including man characteristics as cofounders. We found that the mtDNAcn of the thyroid patients was significantly lower than that measured for the control group (p = 0.01). Furthermore the mtDNAcn of the benign group was significantly lower than that measured in the control group (p = 0.0001). A similar significant difference was found between the thyroiditis group and the control group (p = 0.005).
It was observed that mtDNAcn in the malignant group was significantly higher than that measured in the benign group (p = 0.004), which would indicate that it may be used as a diagnostic and therapeutic marker in thyroid diseases.
本研究旨在确定甲状腺炎、良性结节或恶性结节患者血液样本中的线粒体 DNA(mtDNA)拷贝数与健康个体是否不同,并研究 mtDNAcn 是否具有区分不同甲状腺疾病的能力。
本研究包括主要组,即甲状腺患者组和对照组。甲状腺患者组包括 30 例恶性结节患者、33 例良性结节患者和 31 例甲状腺炎患者,而对照组由 21 名健康个体组成。采集患者治疗前的血样。评估组间结果。
我们无法找到足够数量的符合条件的参与者来匹配组。同样,由于疾病流行在性别方面存在差异,因此不可能根据性别对人群进行配对。相反,使用包括男性特征作为混杂因素的调整模型来分析结果。我们发现甲状腺患者的 mtDNAcn 明显低于对照组(p=0.01)。此外,良性组的 mtDNAcn 明显低于对照组(p=0.0001)。甲状腺炎组与对照组之间也发现了类似的显著差异(p=0.005)。
观察到恶性组的 mtDNAcn 明显高于良性组(p=0.004),这表明它可能被用作甲状腺疾病的诊断和治疗标志物。